Targeted Radiation Therapy for Non-muscle Invasive Bladder Cancer
Targeted Alpha Therapeutics has developed a novel, highly targeted treatment for bladder cancer with fewer side effects.
We combine the specificity of an antibody with the effectiveness of radiation therapy.
We use targeted α-particle therapy, an exquisite tool for treating certain cancers for which limited therapeutic options are available.
Localized, tumor-specific radiotherapy for use in superficial bladder tumors (nothing in the blood or circulation)
We target overexpressed EGFR1 and EGFR2 cancer proteins with Bi-213
At diagnosis, approximately 75% of patients have cancer that has not yet invaded the muscular wall of the bladder (Figure 1). A crucial characteristic of bladder cancer cells is the overexpression of two proteins EGFR1 and EGFR2 on their surface. Our technology arms two FDA-approved, therapeutic antibodies, cetuximab and trastuzumab, with Bi-213 as a novel drug product (Figure 2). These antibodies bind to EGFR1 and EGFR2, respectively. The drug conjugate will be used for treatment of bladder cancer by direct installation in the bladder with current standard of care treatment.
Figure 1
Figure 2
The final commercial product will be a FDA-approved “kit” formulation of the targeting agents, in vials that are ready to radiolabel with Bi-213, which is produced by our proprietary Bi-213 generator device. The final drug formulations will be ready for patient injection after simple quality control assays, effectively addressing the current challenges to this technology of high cost, limited availability, and the presence of impurities.